Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 19;5(5):CD015819.
doi: 10.1002/14651858.CD015819.

Perioperative immunotherapy strategies for resectable non-small cell lung cancer

Corynne Marchal  1 , Guillaume Eberst  2   3 , François Calais  4 , Virginie Westeel  2   3 , Reem Malouf  5
Affiliations

Perioperative immunotherapy strategies for resectable non-small cell lung cancer

Corynne Marchal et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To compare, via a network meta-analysis, the effectiveness and safety of different immunotherapy agents that are administered in a perioperative setting to people with resectable non small-cell lung cancer To perform indirect comparisons in order to generate a clinically meaningful hierarchy of perioperative strategies of immunotherapy administration for overall survival in operable people with resectable non small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Corynne Marchal declares that she has no conflict of interest. She is Managing Editor for the Cochrane Lung Cancer Group but was not involved in the editorial process for this protocol.

Guillaume Eberst reports having received consultancy fees from Amgen, AstraZeneca, Bristol‐Myers Squibb, Merck Sharp and Dohme, Novartis, and Pfizer Cananda Inc.

François Calais declares that he has no conflict of interest. He is Information Specialist for the Cochrane Lung Cancer Group but was not involved in the editorial process for this protocol.

"Virginie Westeel reports ‘relationship/activity’ leading to personal payments with AMGEN" (speaker bureau, consultancy fees, scientific committee, scientific advisory board, and travel expenses); AstraZeneca (scientific advisory board, scientific committee, speaker bureau, and travel expenses); Bristol‐Myers‐Squibb (speaker bureau and travel expenses); IPSEN Biopharmaceuticals Inc (board of experts); Janssen pharmaceuticals (travel expenses); Merck Sharp and Dohme (speaker bureau, scientific committee, travel expenses); Roche (scientific committee, speaker bureau, and travel expenses); Sanofi (speaker bureau, travel expenses). VW is Co‐ordinating Editor for the Cochrane Lung Cancer Group but was not involved in the editorial process for this review.

Reem Malouf declares that she has no conflict of interest.

Figures

1
1
Network graph
See this image and copyright information in PMC

References

Additional references

Aaronson 1993
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: Journal of the National Cancer Institute 1993;85:365-76. - PubMed
Aredo 2024
    1. Aredo JV, Wakelee HA. Top advances of the year: perioperative therapy for lung cancer. Cancer 2024;130(17):2897-903. [DOI: 10.1002/cncr.35357] - DOI - PubMed
Banna 2024
    1. Banna GL, Hassan MA, Signori A, Giunta EF, Maniam A, Anpalakhan S, et al. Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. JAMA Network Open 2024;7(4):e246837. - PMC - PubMed
Bergman 1994
    1. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. European Journal of Cancer 1994;30:635-42. - PubMed
Caldwell 2005
    1. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal 2005;331(7521):897-900. - PMC - PubMed
Capella 2024
    1. Capella MP, Pang SA, Magalhaes MA, Esfahani K. A review of immunotherapy in non-small-cell lung cancer. Current Oncology 2024;31(6):3495-512. - PMC - PubMed
Cascone 2018
    1. Cascone T, Hamdi H, Zhang F, Poteete A, Li L, Hudgens CW, et al. Abstract 1719: superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer. Cancer Research 2018;Suppl 13:1719.
Cascone 2024
    1. Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. New England Journal of Medicine 2024;390(19):1756-69. - PubMed
Chaimani 2017
    1. Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Additional considerations are required when preparing a protocol for a systematic review with multiple interventions. Journal of Clinical Epidemiology 2017;83:65-74. - PubMed
Chaimani 2019
    1. Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G. Chapter 11: Undertaking network meta-analyses (chapter last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024. Available from https://training.cochrane.org/handbook.
Chaimani 2021
    1. Chaimani A, Porcher R, Sbidian É, Mavridis D. A Markov chain approach for ranking treatments in network meta-analysis. Statistics in Medicine 2021;40(2):451-64. - PMC - PubMed
CINeMA 2020 [Computer program]
    1. CINeMA: software for semi-automated assessment of the confidence in the results of network meta-analysis. Papakonstantinou T, Nikolakopoulou A, Higgins JP, Egger M, Salanti G. Campbell Systematic Reviews, 2020. Available at https://cinema.ispm.unibe.ch. - PMC - PubMed
Cipriani 2013
    1. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Annals of Internal Medicine 2013;159(2):130-7. - PubMed
Conroy 2023
    1. Conroy M, Forde PM. Advancing neoadjuvant immunotherapy for lung cancer. Nature Medicine 2023;29(3):533-4. - PubMed
Covidence [Computer program]
    1. Covidence. Version accessed 16 April 2025. Melbourne, Australia: Veritas Health Innovation, 2025. Available at https://www.covidence.org.
CTCAE V4 2009
    1. US Department of Health and Human Services - National Institutes of Health - National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
Deeks 2024
    1. Deeks JJ, Higgins JP, Altman DG, McKenzie JE, Veroniki AA (editors). Chapter 10: analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.1 (updated May 2025). Cochrane, 2025. Available from https://training.cochrane.org/handbook.
Desai 2023
    1. Desai AP, Adashek JJ, Reuss JE, West HJ, Mansfield AS. Perioperative immune checkpoint inhibition in early-stage non-small cell lung cancer: a review. JAMA Oncology 2023;9(1):135-42. - PubMed
Detterbeck 2024
    1. Detterbeck FC, Woodard GA, Bader AS, Dacic S, Grant MJ, Park HS, et al. The proposed ninth edition TNM classification of lung cancer. Chest 2024;166(4):882-95. [DOI: 10.1016/j.chest.2024.05.026] - DOI - PubMed
Dunne 2024
    1. Dunne EG, Fick CN, Isbell JM, Chaft JE, Altorki N, Park BJ, et al. The emerging role of immunotherapy in resectable non-small cell lung cancer. Annals of Thoracic Surgery 2024;118(1):119-29. - PMC - PubMed
Edge 2010
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology 2010;17:1471-4. [DOI: 10.1245/s10434-010-0985-4] - DOI - PubMed
Ettinger 2022
    1. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2022;20(5):497-530. - PubMed
Felip 2021
    1. Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398:1344-57. - PubMed
Forde 2018
    1. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. New England Journal of Medicine 2018;378:1976-86. - PMC - PubMed
Forde 2022
    1. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. New England Journal of Medicine 2022;386:1973-85. - PMC - PubMed
Franco 2021
    1. Franco JV, Jung JH, Imamura M, Borofsky M, Omar MI, Escobar Liquitay CM, et al. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No: CD013656. [CENTRAL: CD013656] [DOI: 10.1002/14651858.CD013656.pub2] - DOI - PMC - PubMed
Früh 2008
    1. Früh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. Journal of Clinical Oncology 2008;26:3573-81. - PubMed
GLOBOCAN 2020
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians 2020;71(3):202-49. - PubMed
Goldstraw 2016
    1. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology 2016;11(1):39-51. - PubMed
Herath 2022
    1. Herath S, Sadeghi Rad H, Radfar P, Ladwa R, Warkiani M, O’Byrne K, et al. The role of circulating biomarkers in lung cancer. Frontiers in Oncology 2022;11:801269. - PMC - PubMed
Herbst 2008
    1. Herbst RS, JV Heymach, SM Lippman. Lung cancer. New England Journal of Medicine 2008;359(13):1367-80. - PMC - PubMed
Heymach 2023
    1. Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. In: Presented at 2023 AACR Annual Meeting; April 14-19, 2023; Orlando, FL. Abstract CT005. 2023.
Higgins 2013
    1. Higgins J. Handout S9-L Identifying and addressing inconsistency in network meta-analysis. Cochrane Comparing Multiple Interventions Methods Group Cochrane training event, Oxford, March 2013. Available at https://methods.cochrane.org/cmi/sites/methods.cochrane.org.cmi/files/up....
Higgins 2019
    1. Higgins JPT, Savovic J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024. Available from https://training.cochrane.org/handbook.
Huang 2024
    1. Huang J, Osarogiagbon RU, Giroux DJ, Nishimura KK, Bille A, Cardillo G, et al, Prognostic Factors Committee. The International Association for the Study of Lung Cancer staging project for lung cancer: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. Journal of Thoracic Oncology 2024;19(5):766-85. - PubMed
Hung 2020
    1. Hung RJ, Gazdar AF, Didkowska J, Johansson M. Lung cancer continues to be the leading cause of cancer death. In: Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer, 2020. Available from https://www.ncbi.nlm.nih.gov/books/NBK606485/. - PubMed
Jansen 2013
    1. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Medicine 2013;11(1):1-8. - PMC - PubMed
Lathyris 2010
    1. Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JP. Industry sponsorship and selection of comparators in randomized clinical trials. European Journal of Clinical Investigation 2010;40(2):172-82. - PubMed
Le Pechoux 2022
    1. Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncology 2022;23:104-14. - PubMed
Lefebvre 2025
    1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies (last updated March 2025). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.1. Cochrane, 2025. Available from https://training.cochrane.org/handbook.
Leiter 2023
    1. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nature Reviews Clinical Oncology 2023;20(9):624-39. - PubMed
Li 2020
    1. Li JJN, Karim K, Sung M, Le LW, Lau SCM, Sacher A, et al. Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. Lung Cancer (Amsterdam, Netherlands) 2020;150:159-63. - PubMed
Lim 2009
    1. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. Journal of Thoracic Oncology 2009;4(11):1380-8. - PubMed
Lu 2004
    1. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004;23(20):3105-24. - PubMed
Mavridis 2015
    1. Mavridis D, White IR, Higgins JP, Cipriani A, Salanti G. Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis. Statistics in Medicine 2015;34(5):721-41. - PMC - PubMed
McKenzie 2019
    1. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV. Chapter 9: Summarizing study characteristics and preparing for synthesis (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 6.5 (updated August 2024). Cochrane, 2024. Available from https://training.cochrane.org/handbook.
Microsoft Excel [Computer program]
    1. Microsoft Excel. Microsoft Corporation, 2018. Available at https://office.microsoft.com/excel.
Ng 2019
    1. Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, et al. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer 2019;125(7):1038-49. - PubMed
Oken 1982
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982;6:649-55. - PubMed
O’Brien 2022
    1. O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncology 2022;23:1274-86. - PubMed
Patel 2023
    1. Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. New England Journal of Medicine 2023;389(9):813-23. - PMC - PubMed
Peng 2023
    1. Peng Y, Li Z, Fu Y, Pan Y, Zeng Y, Liu J, et al. Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer. Frontiers in Oncolology 2023;13:1011810. - PMC - PubMed
Pignon 2008
    1. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al, LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology 2008;26(21):3552-9. [DOI: 10.1200/JCO.2007.13.9030] - DOI - PubMed
R 2021 [Computer program]
    1. R: a language and environment for statistical computing. R Core Team. Vienna, Austria: R Foundation for Statistical Computing, 2021. Available at https://www.r-project.org/.
RevMan 2025 [Computer program]
    1. Review Manager (RevMan). Version 9.1.0. The Cochrane Collaboration, 2025. Available at https://revman.cochrane.org.
Rhodes 2015
    1. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. Journal of Clinical Epidemiology 2015;68(1):52-60. - PMC - PubMed
Salanti 2011
    1. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71. - PubMed
Salanti 2014
    1. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PloS One 2014;9(7):e99682. - PMC - PubMed
Schünemann 2023
    1. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, on behalf of the Cochrane GRADEing Methods Group. Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 6.5 (updated August 2024). Cochrane, 2024. Available from https://training.cochrane.org/handbook.
Song 2003
    1. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ (Clinical Research Ed) 2003;326(7387):472. - PMC - PubMed
Turner 2012
    1. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818-27. - PMC - PubMed
Veluswamy 2016
    1. Veluswamy RR, Levy B, Wisnivesky JP. Chemotherapy in elderly patients with nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine 2016;22(4):336-43. - PubMed
Veroniki 2013
    1. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. International Journal of Epidemiology 2013;42(1):332-45. - PMC - PubMed
Wakelee 2017
    1. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara, DR, Graziano SL, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology 2017;18:1610-23. - PMC - PubMed
Wakelee 2023
    1. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, et al, for the KEYNOTE-671 investigators. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. New England Journal of Medicine 2023;389:491-503. [DOI: 10.1056/NEJMoa2302983] - DOI - PMC - PubMed
Wei 2011
    1. Wei S, Asamura H, Kawachi R, Sakurai H, Watanabe SI. Which is the better prognostic factor for resected non-small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification? Journal of Thoracic Oncology 2011;6(2):310-8. - PubMed
White 2008
    1. White IR, Higgins JP, Wood AM. Allowing for uncertainty due to missing data in meta-analysis-part 1: two-stage methods. Statistics in Medicine 2008;27(5):711-27. - PubMed
White 2012
    1. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Research Synthesis Methods 2012;3(2):111-25. - PMC - PubMed
Yepes‐Nuñez 2019
    1. Yepes-Nuñez JJ, Li SA, Guyatt G, Jack SM, Brozek JL, Beyene J, et al. Development of the summary of findings table for network meta-analysis. Journal of Clinical Epidemiology 2019;115:1-13. [DOI: 10.1016/j.jclinepi.2019.04.018] - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources